Hawthorn Pharmaceuticals Inc. and parent company Cypress Pharmaceutical Inc. have agreed to pay $2.8 million to resolve allegations that the company sold three skin-treatment drugs which were not approved by the FDA as safe and effective.  The company allegedly misrepresented the approval status of the drugs in its quarterly filings with CMS, as well as the drugs’ eligibility for coverage under government healthcare programs.

Read the entire press release, “Mississippi Pharmaceutical Firm and CEO to Pay $2.8 Million to Resolve Allegations of Illegal Marketing of Unapproved Drugs”